2K62 image
Deposition Date 2008-07-03
Release Date 2008-11-04
Last Version Date 2024-05-29
Entry Detail
PDB ID:
2K62
Title:
NMR solution structure of the supramolecular adduct between a liver cytosolic bile acid binding protein and a bile acid-based Gd(III)-chelate
Biological Source:
Source Organism:
Gallus gallus (Taxon ID: 9031)
Host Organism:
Method Details:
Experimental Method:
Conformers Calculated:
200
Conformers Submitted:
7
Selection Criteria:
structures with the lowest energy
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Liver fatty acid-binding protein
Gene (Uniprot):FABP1
Chain IDs:A
Chain Length:125
Number of Molecules:1
Biological Source:Gallus gallus
Primary Citation
Solution structure of the supramolecular adduct between a liver cytosolic bile acid binding protein and a bile acid-based gadolinium(III)-chelate, a potential hepatospecific magnetic resonance imaging contrast agent.
J.Med.Chem. 51 6782 6792 (2008)
PMID: 18939814 DOI: 10.1021/jm800820b

Abstact

Bile acid-conjugated gadolinium chelates were shown to display promising features for the development of hepatospecific constrast agents for magnetic resonance imaging (MRI). The study of the pharmacokinetics of these compounds should address their possible interaction with the bile acid protein transporters. We have previously shown that a 5beta-cholanoic acid-based contrast agent is efficiently internalized in hepatocytes and is able to bind to a liver bile acid binding protein (BABP) in vitro. Here we report the solution structure of the adduct between a BABP and a gadolinium chelate/bile acid conjugate. The identification of unambiguous intermolecular distance restraints was possible through 3D edited/filtered NOESY-HSQC experiments, together with distance information derived from paramagnetic relaxation enhancements. These intermolecular contacts were used for the structure determination of the complex, using the data-driven docking software HADDOCK. The obtained results represent the starting point for the design of new and more efficient MRI contrast agents.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback